Drug Trial Radar · NCT06287944
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
May 19, 2029
Study completion May 19, 2029
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI) as conditioning treatment for donor stem cell transplant in patients with high-risk acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Radioimmunotherapy is treatment with a radioactive substance that is linked to a monoclonal antibody, such as daratumumab, that will find and attach to cancer cells. Radiation given off by the radioisotope my help kill the cancer cells. Chemotherapy drugs, such as fludarabine and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. TMLI is a targeted form of body radiation that targets marrow, lymph node chains, and the spleen. It is designed to reduce radiation-associated side effects and maximize therapy effect. Actinium Ac 225-DOTA-daratumumab combined with fludarabine, melphalan and TMLI may be safe, tolerable, and/or effective as conditioning treatment for donor stem cell transplant in patients with high-risk AML, ALL, and MDS.
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-DaratumumabBiological
Given IV
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspiration
Computed TomographyProcedure
Undergo CT
DaratumumabBiological
Given IV
EchocardiographyProcedure
Undergo echocardiography
FludarabineDrug
Given IV
Hematopoietic Cell TransplantationProcedure
Undergo SCT
Indium In 111-DOTA-DaratumumabBiological
Given IV
MelphalanDrug
Given IV
Multigated Acquisition ScanProcedure
Undergo MUGA
Radionuclide ImagingProcedure
Undergo nuclear scan
Single Photon Emission Computed TomographyProcedure
Undergo SPECT scan
SirolimusDrug
Given sirolimus
TacrolimusDrug
Given tacrolimus
Total Marrow and Lymphoid IrradiationRadiation
Undergo TMLI
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (CTCAE)Time frame: Up to 2 years post-transplant
- Incidence of adverse events (Bearman)Time frame: Up to 2 years post-transplant
- Dose limiting toxicity (DLT)Time frame: Up to 30 days post-stem cell infusion
- Maximum tolerated dose/recommended phase II dose (MTD/RP2D)Time frame: Up to 30 days post stem cell infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.